A study out of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University has resulted in the discovery of a promising new antimalarial compound.
The Lung Health Foundation and Canada’s Global Nexus for Pandemics and Biological Threats have partnered to provide Canadians with evidence-based, timely information on COVID-19 vaccine efficacy, infectious respiratory diseases and other public health measures put in place to manage risk and improve peoples’ health.
Canada’s Global Nexus for Pandemics and Biological Threats at McMaster University and the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) have signed a partnership agreement that brings the two institutions together to accelerate vaccine and drug development, human clinical trials and create new diagnostic tools.
McMaster logo
McMaster logo
